Strongbridge Biopharma plc.
SBBP
SBBP was delisted on the 5th of October, 2021.
54 hedge funds and large institutions have $190M invested in Strongbridge Biopharma plc. in 2017 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 5 reducing their positions, and 5 closing their positions.
340% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 5
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
26% more funds holding
Funds holding: 43 → 54 (+11)
20% more capital invested
Capital invested by funds: $158M → $190M (+$32M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.34M |
| 2 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$6.19M |
| 3 |
BlackRock
New York
|
+$3.27M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.15M |
| 5 |
BC
Broadfin Capital
New York
|
+$1.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$5.91M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$3.19M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$117K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$99K |
| 5 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$83K |
SBBP Hedge Fund Activity: Q4 2017 in Review
54 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2017, worth a combined $190M — up 20% from $158M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SBBP positions and 5 closed out — a net gain of 11 holders — while 22 added to existing stakes and 5 trimmed.
The largest buyer was Armistice Capital, adding an estimated $7.34M. The largest seller was Boxer Capital, exiting entirely with an estimated $5.91M sold.
- 54 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2017, up from 43 in Q3 2017.
- Funds reported $190M of Strongbridge Biopharma plc. stock for Q4 2017, up 20% quarter-over-quarter.
- 16 funds opened new Strongbridge Biopharma plc. positions in Q4 2017 and 5 closed out, a net change of +11 holders.
- The largest Strongbridge Biopharma plc. buyer in Q4 2017 was Armistice Capital, an estimated $7.34M added.
- The largest Strongbridge Biopharma plc. seller in Q4 2017 was Boxer Capital, an estimated $5.91M sold.
Based on aggregated 13F filings for Q4 2017.